Clinical trial
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma…
NCT00103662 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00103662 |
|---|---|
| Title | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo |
| Enrollment | 302 |
| Start date | Jan 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Feb 14, 2005 |
| Last update posted | Mar 13, 2014 |
| Countries | Canada, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: